Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 4/20 | 0.51 |
| ▸ | RBP4 | P02753 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 4/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083458 | 0.83 | HMOX1 (0.51) | HMOX1RBP4MAPK1MAPK3MAP2K1 | |
| SCHEMBL4514777 | 0.80 | MAPK1 (0.47) | HMOX1RBP4MAPK1MET | |
| SCHEMBL4519501 | 0.78 | CTSS (0.54) | CTSS | |
| SCHEMBL5257069 | 0.76 | MAPK1 (0.63) | HMOX1RBP4MAPK1MAPK3MAP2K1 | |
| SCHEMBL4531581 | 0.76 | CTSS (0.70) | CTSS | |
| SCHEMBL4086151 | 0.76 | RBP4 (0.49) | HMOX1RBP4MAPK1METCTSS | |
| SCHEMBL4526096 | 0.75 | CTSS (0.60) | CTSS | |
| SCHEMBL9889385 | 0.75 | MAPT (0.55) | MAPK1MAPK3MAP2K1METFLT3 | |
| SCHEMBL4713595 | 0.74 | MET (0.50) | HMOX1MAPK1MAPK3MAP2K1MET | |
| SCHEMBL4532938 | 0.73 | MET (0.50) | HMOX1RBP4MAPK1MAPK3MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | CTSS, CTSE, CTSK | HMOX1 1683/4885RBP4 2644/4885MAPK1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.